Literature DB >> 12819045

Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?

Peter J van den Elsen, Nienke van der Stoep.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12819045      PMCID： PMC1868151          DOI： 10.1016/s0002-9440(10)63664-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  28 in total

Review 1.  Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet.

Authors:  C Benoist; D Mathis
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

Review 2.  Sequences and factors: a guide to MHC class-II transcription.

Authors:  L H Glimcher; C J Kara
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

3.  Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.

Authors:  A Muhlethaler-Mottet; L A Otten; V Steimle; B Mach
Journal:  EMBO J       Date:  1997-05-15       Impact factor: 11.598

4.  Introduction of exogenous class II trans-activator in MHC class II-deficient ABI fibroblasts results in incomplete rescue of MHC class II antigen expression.

Authors:  A Peijnenburg; S J Gobin; M C van Eggermond; B C Godthelp; N van Graafeiland; P J van den Elsen
Journal:  J Immunol       Date:  1997-09-15       Impact factor: 5.422

5.  Induction of MHC class I expression by the MHC class II transactivator CIITA.

Authors:  B K Martin; K C Chin; J C Olsen; C A Skinner; A Dey; K Ozato; J P Ting
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

6.  Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA.

Authors:  S J Gobin; A Peijnenburg; V Keijsers; P J van den Elsen
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

Review 7.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.

Authors:  F Garrido; F Ruiz-Cabello; T Cabrera; J J Pérez-Villar; M López-Botet; M Duggan-Keen; P L Stern
Journal:  Immunol Today       Date:  1997-02

8.  Lymphocytic infiltration in juvenile thyroid carcinoma.

Authors:  H Kamma; K Fujii; T Ogata
Journal:  Cancer       Date:  1988-11-01       Impact factor: 6.860

Review 9.  The role of surface HLA-A,B,C molecules in tumour immunity.

Authors:  P Möller; G J Hämmerling
Journal:  Cancer Surv       Date:  1992

10.  DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells.

Authors:  Shawn P Murphy; Renae Holtz; Nicole Lewandowski; Thomas B Tomasi; Hiroshi Fuji
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422
View more
  3 in total

1.  Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.

Authors:  Laura Pisapia; Giovanna Del Pozzo; Pasquale Barba; Alessandra Citro; Paul E Harris; Antonella Maffei
Journal:  Results Immunol       Date:  2012-09-27

2.  A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.

Authors:  Xuan Zou; Zhihuang Hu; Changjing Huang; Jianhua Chang
Journal:  Med Sci Monit       Date:  2020-07-02

3.  Functional disruption of human leukocyte antigen II in human embryonic stem cell.

Authors:  Haide Chen; Yang Li; Xijuan Lin; Di Cui; Chun Cui; Hui Li; Lei Xiao
Journal:  Biol Res       Date:  2015-10-27       Impact factor: 5.612
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.